Adhera Therapeutics will develop MLR-1019 (armesocarb), a treatment candidate for easing Parkinson’s disease symptoms, following a licensing agreement with Melior Pharmaceuticals II. The therapy is the only one in development that’s designed to treat both
Anxiety is the secret poison of Parkinson’s disease. While it is not a symptom many people associate with the condition, many of us still suffer from it. What is anxiety? Anxiety involves feelings of worry,
People with Parkinson’s disease who combine standard medication with various types of acupuncture treatments may see improvements in their motor function and quality of life, a review study from China suggests. However, its researchers noted
The mesencephalic locomotor region, a brain region previously thought to control only walking and other forms of locomotion in vertebrates, also regulates postural changes and other movements, according to a study in mice. “It was
Two South Australian hospitals team up with a biotechnology company to trial faecal transplants to treat an uncomfortable symptom of Parkinson’s disease. …
My sister Bev, who has stage 3 Parkinson’s disease (PD), has always been an animal lover. I asked her to share with me how her pets have helped her through her illnesses. “I’ve had dogs
Inhibikase Therapeutics has received clearance from the U.S. Food and Drug Administration (FDA) to start a Phase 1 clinical trial evaluating its investigational, once-daily, oral medicine IkT-148009 in patients with Parkinson’s disease. The clearance comes after the
Parkinson’s vaccine candidate Affitope PD01, along with maker Affiris’ portfolio of other alpha-synuclein-targeting therapies, was acquired by AC Immune in a recent deal valued at nearly $60 million. “We believe very strongly that active vaccination
Hypertension, or high blood pressure, almost doubles the risk of developing Parkinson’s disease in people of Han Chinese descent living in Singapore, a case-controlled study found. In contrast, a comparison of similar studies conducted in
An upcoming Australian study will investigate the potential benefits of pool walking — walking in a swimming pool versus on land — to ease the non-motor symptoms of Parkinson’s disease. The study’s main goal, according
The Parkinson’s Foundation has awarded over $2.2 million in community health grants to 143 programs that will benefit Parkinson’s disease patients across 42 U.S. states, as well as efforts in Australia and Taiwan. This year’s grants, which mark the
A committee of the European Medicines Agency (EMA) is recommending the refusal of marketing authorization for Nouryant (istradefylline) — approved as Nourianz in the U.S. — as a medication for treating off episodes in Parkinson’s